Acurx discontinues Phase 2b ibezapolstat trial early on high cure rates, no safety concerns; Phase 3 accelerated

Acurx Pharmaceuticals, Inc.

Phase 2b discontinued after blinded data showed high clinical cure rates for ibezapolstat and vancomycin, with no emerging safety concerns.
Company expects to advance ibezapolstat to Phase 3 more expeditiously; topline efficacy results to be reported promptly.
Ibezapolstat is first-in-class, FDA QIDP/Fast-Track-designated antibiotic for C. difficile infection, potentially first new antibiotic class in 30+ years.
Decision also influenced by site maintenance costs and slow enrollment due to COVID-19; Independent Data Monitoring Committee will not perform interim analysis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.